Valeant completes buyout of PreCision Dermatology; Novartis changes clinical trial rules;

@FiercePharma: Top-read on FP Monday: EU approves GSK's Mekinist and Novartis will reap the rewards. Article | Follow @FiercePharma

@EricPFierce: Health Canada tells GSK to get its vaccine house in order as flu season approaches. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI: Ackman puts forth his slate of new Allergan directors. Report | Follow @CarlyHFierce

> Valeant Pharmaceuticals ($VRX) has completed the $475 million acquisition of PreCision Dermatology. Release

> Robert J. Hombach, currently chief financial officer for Baxter International ($BAX), will become CFO of the unnamed pharmaceutical company that will be created when Baxter next year spins off its biopharma operations. Release

> The FDA has granted priority to review to Purdue Pharma's tamper-resistant competitor to Zohydro, the pain drug for which the FDA has been criticized for approving by those afraid it will be widely abused. Story

> Novartis ($NVS), which is embroiled in a controversy in Japan over the way researchers handled studies, has amended its requirements for clinical trials by outside researchers. Story

> Mylan ($MYL) has launched a generic of Boehringer Ingelheim's hypertension drug Micardis. Story

> Those on both sides of the debate over legalizing marijuana say it is unlikely the FDA, which is evaluating marijuana's place as a Schedule I drug, will downgrade its classification. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: FDA lowers regulatory bar for neurostimulators to treat headache. Story | Follow @FierceMedDev

@StacyALawrence: Boston Scientific backs Israeli cardio device startup Mvalve with $15M. More | Follow @StacyALawrence

@VarunSaxena2: Check out our special report on the top 10 highest paid med tech CEOs. Feature | Follow @VarunSaxena2

@MichaelGFierce: A tiny, "walking" robot powered by a muscle cell? It could help deliver drugs one day. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Rapid Dx tests for Chagas disease yield quick, reliable results without lab confirmation, according to study. New York Times article | Follow @EmilyWFierce

> Researchers develop realtime, 'nanojuice'-enabled imaging method for gut. Report

> Ulthera device clears FDA for décolleté on heels of Merz acquisition plans. News

> Surgeons tout benefits of Google Glass in operating room. Article

Biotech News

@FierceBiotech: AstraZeneca spreads its virtual reach to cardio R&D with new partnership. News | Follow @FierceBiotech

@JohnCFierce: Intent on closing a deal, AbbVie boosts its bid for Shire to $51B. News | Follow @JohnCFierce

@DamianFierce: So $SHPG has 10 days to consider $ABBV's +11% offer. Press release | Follow @DamianFierce

@EmilyMFierce: European neuroscientists ask for better governance and tough review in EU Human Brain Project. Science story | Follow @EmilyMFierce

> Lilly partners with China's Yabao on diabetes drug. Item

> Boehringer's 'breakthrough' cancer drug comes through in Phase II. Report

> Versant close to capping $300M fund to foster next-gen biotechs. Article

> Novartis' leading CAR-T cancer therapy gains 'breakthrough' status at the FDA. Story

Biotech Research News

> Schizophrenia-linked genetic variation causes abnormal brain cell development. More

> Blocking cell migration could stop cancer spread. Article

> Technique regrows corneas in mice from adult human stem cells. Story

> Chemical switch could be drug target for neurodegenerative disease. More

> AstraZeneca, MRC Technology renew preclinical pact. Item

Pharma Manufacturing News

> Cipla plans U.K. investment as Indian drugmakers await economic reforms. More

> Ingredient price hikes prompt Express Scripts to slash coverage of compounded drugs. Story

> Novo A/S-owned Xellia snaps up Fresenius vial plant to expand in U.S. Report

> Hospira completes Orchid plant takeover to boost API supply security. Item

> Ingredient price hikes prompt Express Scripts to slash coverage of compounded drugs. Story

> Health Canada gives GSK 30 days to show how it will fix its vaccine plant. Article

And Finally... Malaysia's state-owned FELDA plans a $300 million listing on the "life sciences-friendly" Nasdaq as it prepares to bring plant-based drugs to the U.S. Story

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.